Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

<p>Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</p> <p>Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</p> <p>Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.</p&gt

HIV and TB co-infection in South Sudan: a three year retrospective study

Objective To determine the prevalence of HIV/TB co-infection among patients attending the HIV clinic at Juba Teaching Hospital (JTH) from 2011 to 2013. Method and Materials This was a retrospective study using data abstracted from the registration book in the HIV clinic. A data sheet was used to collect relevant variables. Data were entered, organized and analyzed using SPSS Version 20 Software. A p-value of 0.05 or less was considered significant. Results Out of 2,577 patients attending the HIV clinic in JTH from 2011 to 2013, 2,547 (99%) were included in this study. Of these, 27.4% were seen in 2011, 34.1% in 2012 and 38.5% in 2013. There were 1,010 (39.7%) males and 1,537(60.3%) females with a male to female ratio of 2:3. The mean age (x, SD, range) was 30.8 +/-10.8 (0.2-68) years which for males was 33.3+/- 12.2 (1-68) years and 29.1+/-9.5 (0.2-65) years for females. There were 2,318 (91%) HIV mono-infected patients and 229 (9%) HIV/TB co-infected patients. There were 122 HIV/TB co-infected males and 107 females. 39.3% of patients with HIV/TB were aged 25-34 years, and 9.3% were aged 0-14 years. The p-value between the groups and within the groups was statistically significant at p= 0.005. Munuki payam had the highest percentage (31.7%) of HIV/TB co-infection. Conclusion HIV/TB remains a major challenging health problem with a prevalence of 9%

The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline characteristics of the study population

<p>Objectives: Ivabradine is a selective heart rate-lowering agent that acts by inhibiting the pacemaker current If in sinoatrial node cells. Patients with coronary artery disease and left ventricular dysfunction are at high risk of death and cardiac events, and the BEAUTIFUL study was designed to evaluate the effects of ivabradine on outcome in such patients receiving optimal medical therapy. This report describes the study population at baseline.</p> <p>Methods: BEAUTIFUL is an international, multicentre, randomized, double-blind trial to compare ivabradine with placebo in reducing mortality and cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction (ejection fraction <40%).</p> <p>Results: A total of 10,917 patients were randomized. At baseline, their mean age was 65 years, 83% were male, 98% Caucasian, 88% had previous myocardial infarction, 37% had diabetes, and 40% had metabolic syndrome. Mean ejection fraction was 32% and resting heart rate was 71.6 bpm. Concomitant medications included beta-blockers (87%), renin-angiotensin system agents (89%), antithrombotic agents (94%), and lipid-lowering agents (76%).</p> <p>Conclusions: Main results from BEAUTIFUL are expected in 2008, and should show whether ivabradine, on top of optimal medical treatment, reduces mortality and cardiovascular events in this population of high-risk patients.</p&gt